| Detected | Trial | Change |
|---|---|---|
| 2026-06-25 | NCT02838420 A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib… |
Trial completed |
| 2026-06-25 | NCT02838420 A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib… |
date change Completion moved earlier: 2026-06-30 -> 2026-05-11 |
| 2026-06-24 | NCT05910528 Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease |
date change Primary completion moved earlier: 2030-12-31 -> 2026-12-31 |
| 2026-06-24 | NCT05910528 Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease |
date change Completion moved earlier: 2030-12-31 -> 2026-12-31 |
| 2026-06-24 | NCT07054190 A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated… |
Trial arms changed: 3 -> 4 |
| 2026-06-24 | NCT07054190 A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated… |
Trial sites expanded: 30 -> 33 locations |
| 2026-06-24 | NCT07558915 A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma… |
Recruitment opened |
| 2026-06-24 | NCT07282574 A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of… |
Trial sites expanded: 73 -> 91 locations |
| 2026-06-24 | NCT07351045 A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With… |
Trial sites expanded: 73 -> 128 locations |
| 2026-06-24 | NCT04777331 A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants… |
date change Completion pushed: 2026-12-30 -> 2031-06-30 |
| 2026-06-24 | NCT06850922 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603… |
Trial completed |
| 2026-06-24 | NCT06850922 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603… |
Enrollment reduced: 546 -> 388 participants |
| 2026-06-24 | NCT06850922 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603… |
date change Primary completion moved earlier: 2027-04-30 -> 2026-05-19 |
| 2026-06-24 | NCT06850922 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603… |
date change Completion moved earlier: 2027-04-30 -> 2026-06-19 |
| 2026-06-24 | NCT07555938 Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in… |
Trial sites expanded: 4 -> 7 locations |
| 2026-06-24 | NCT07351058 A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With… |
Trial sites expanded: 61 -> 122 locations |
| 2026-06-23 | NCT07059273 A COPD Data Registry for Participants With Frequent Exacerbations |
overall status: "Not Yet Recruiting" → "Withdrawn" |
| 2026-06-23 | NCT07059273 A COPD Data Registry for Participants With Frequent Exacerbations |
Enrollment reduced: 3000 -> 0 participants |
| 2026-06-23 | NCT05808764 A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With… |
Trial completed |
| 2026-06-23 | NCT05808764 A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With… |
Enrollment increased: 10 -> 11 participants |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-25 | NCT07667322 A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and… | Phase 1 | Recruiting |
| 2026-06-24 | NCT07665723 An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's… | Phase 1 | Recruiting |
| 2026-06-12 | NCT07643831 Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2- Early or… | Available | |
| 2026-06-05 | NCT07629583 To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus… | Phase 1 | Not Yet Recruiting |
| 2026-06-04 | NCT07626515 A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in… | Phase 1 | Not Yet Recruiting |
| 2026-06-02 | NCT07620392 An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants… | Phase 2 | Not Yet Recruiting |
| 2026-06-01 | NCT07617337 AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer | Phase 1 | Not Yet Recruiting |
| 2026-05-27 | NCT07609719 A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple… | Phase 4 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT05861986 | A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early… | Muscular Atrophy, Spinal | Recruiting |
| NCT07483450 | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of… | Relapsing Multiple Sclerosis | Recruiting |
| NCT06274515 | A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies | Breast Cancer | Recruiting |
| NCT05861999 | A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric… | Muscular Atrophy, Spinal | Recruiting |
| NCT04853251 | A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related… | Neovascular Age-related Macular Degeneration | Recruiting |
| NCT05232929 | Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA) | Spinal Muscular Atrophy | Active, Not Recruiting |
| NCT05181618 | A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants… | Severe Hemophilia A | Active, Not Recruiting |
| NCT06795048 | A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants… | Neovascular Age-related Macular Degeneration (nAMD) | Active, Not Recruiting |
| NCT07025811 | A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants… | Dry Eye Disease | Active, Not Recruiting |
| NCT05224102 | A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented… | Diabetic Macular Edema | Active, Not Recruiting |
| NCT07609719 | A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple… | Multiple Sclerosis | Not Yet Recruiting |
| Phase 3 | |||
| NCT06675955 | An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and… | Multiple Sclerosis | Recruiting |
| NCT06094010 | A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants… | Influenza | Recruiting |
| NCT05894239 | A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo… | Metastatic Breast Cancer | Recruiting |
| NCT05878769 | A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic… | Chronic Obstructive Pulmonary Disease | Recruiting |
| NCT06084936 | A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in… | Lymphoma | Recruiting |
| NCT06588855 | A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also… | Moderately to Severely Active Ulcerative Colitis | Recruiting |
| NCT06790693 | A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and… | Breast Cancer | Recruiting |
| NCT06819878 | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With… | Moderately to Severely Active Crohns Disease | Recruiting |
| NCT07169578 | A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | Alzheimers Disease | Recruiting |
| NCT03683251 | Extension Study for the Port Delivery System With Ranibizumab (Portal) | Neovascular Age-Related Macular Degeneration | Recruiting |
| NCT06065748 | A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a… | Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer | Recruiting |
| NCT07174310 | A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in… | Parkinson's Disease | Recruiting |
| NCT07177352 | Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's… | Alzheimers Disease | Recruiting |
| NCT05503264 | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics… | NMDAR Autoimmune Encephalitis | Recruiting |